After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Protalix BioTherapeutics Inc. (PLX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.12, or -3.81%, to $3.03. The Protalix BioTherapeutics Inc. has recorded 64,842 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Stocks Info
PLX belongs to the Healthcare sector of the AMEX while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.15 and fluctuated between $3.1500 as its day high and $2.6000 as its day low. The current market capitalization of Protalix BioTherapeutics Inc. is $173.60M. A total of 5.43 million shares were traded on the day, compared to an average of 1.34M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, PLX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 0 SELLs from insiders. Insiders purchased 110,000 shares during that period but sold 0.
In the most recent transaction, Schwartz Aharon bought 110,000 shares of PLX for 1.42 per share on Jan 03. After the transaction, the Director now owns 174,000 company shares.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for PLX in the last 3 months, the mean price target is $11.00 with high estimates of $11.00 and low estimates of $11.00. In terms of 52-week highs and lows, PLX has a high of $2.94 and a low of $0.98.
As of this writing, PLX has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0. The company reported an EPS of $-0.07 in the last quarter, which was 53.30% higher than expectations of $-0.15.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. PLX’s latest balance sheet shows that the firm has $38.98M in Cash & Short Term Investments as of fiscal 2021. There were $33.47M in debt and $33.18M in liabilities at the time. Its Book Value Per Share was $-0.21, while its Total Shareholder’s Equity was $-6.04M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PLX is Buy with a score of 0.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
